- Investors & Media
- Investors & Media
- Contact Us
Expects to Report Top-Line Results in First Quarter 2014; Preparations Underway for European Regulatory Filing in Second Half of 2014
Experienced Executive to Expand Opportunities for the Company's Protein Therapeutics Platform
New results in T1D pediatric patients indicate 60% of patients still maintain active pancreatic beta cells that secrete self-insulin approximately 10 months after last Glassia treatment
Large percentage of patients have very good glycemic control; Phase II/III trial to initiate by end of 2013
European Phase 2/3 trial of inhaled AAT for AATD to complete by year-end
Adjusting 2013 revenue guidance; product sales from Baxter remain on track
Conference call begins today at 8:30 a.m. Eastern time
Kamada management will host an investment community conference call on Tuesday, October 29, 2013 beginning at 8:30 a.m. Eastern time
NESS ZIONA, Israel (September 4, 2013) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Gil Efron, Kamada's Chief Financial Officer, will deliver a corporate overview at two upcoming investment conferences in New York City. Rodman and Renshaw's 15th Annual Global Healthcare Conference taking place from […]
This study examined transplant survival of pancreatic islets originating in other (xeno) species donors. in combination with Glassia, there was a significant time extension in graft acceptance and a higher rate of graft acceptance compared with groups that did not receive Glassia.
the Company was granted two key patents related to its novel Alpha-1 Antitrypsin (AAT) product to treat respiratory diseases.
Kamada Ltd. today announced the pricing of its initial public offering in the United States of 5,582,636 ordinary shares at a price to the public of $9.25 per ordinary share.
Total revenue from sales of Glassia in USA is expected to grow: minimum revenues of approximately $165 million